T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody Fragment
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
A major difficulty in treating cancer is the inability to differentiate between normal and tumor cells. The immune system differentiates tumor from normal cells by T cell receptor (TCR) binding of tumor-associated peptides bound to Major Histocompatibility Complex (pMHC) molecules. The peptides, derived from the tumor-specific proteins, are presented by MHC proteins, which then serve as cancer markers. The TCR is a difficult protein to use as a recombinant protein because of production issues and has poor affinity for pMHC; therefore, it is not a good choice for use as a tumor identifier outside of the immune system. We constructed a synthetic antibody-fragment (Fab) library in the phage-display format and isolated antibody-fragments that bind pMHC with high affinity and specificity. One Fab, fE75, recognizes our model cancer marker, the Human Epidermal growth factor Receptor 2 (HER2/neu) peptide, E75, bound to the MHC called Human Leukocyte Antigen-A2 (HLA-A2), with nanomolar affinity. The fE75 bound selectively to E75/HLA-A2 positive cancer cell lines in vitro. The fE75 Fab conjugated with (64)Cu selectively accumulated in E75/HLA-A2 positive tumors and not in E75/HLA-A2 negative tumors in an HLA-A2 transgenic mouse as probed using positron emission tomography/computed tomography (PET/CT) imaging. Considering that hundreds to thousands of different peptides bound to HLA-A2 are present on the surface of each cell, the fact that fE75 arrives at the tumor at all shows extraordinary specificity. These antibody fragments have great potential for diagnosis and targeted drug delivery in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R., & Germain, R. N. (1997) · Immunity · doi:10.1016/s1074-7613(00)80447-1 · Cited by 669
The fibronectin type III domain as a scaffold for novel binding proteins
Koide, A., Bailey, C. W., Huang, X., & Koide, S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2238 · Cited by 585 · cited 1×
“The synthesized gene and the phoA promotor segment were cloned into a phage-display vector, pAS38 [29] in such a way that the heavy chain of the Fab is fused to the carboxyl-terminal 208 residue segment of M13 phage pIII.”
MethodSelf-citation
Cited by
The immune system and response to HER2-targeted treatment in breast cancer
Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 286
Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy
Hu, Y., Liu, C., & Muyldermans, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01442 · Cited by 171
“Considerable efforts have been put into the development of smaller antibody formats (11, 12), such as the naturally derived or recombinant antigen-binding fragment (Fab; ~50 kDa), variable fragment (Fv; ~28 kDa), or single-chain variable fragment (scFv; ~30 kDa) (Figure 1) (13).”
BackgroundStructures of rhodopsin in complex with G-protein-coupled receptor kinase 1
Chen, Q., Plasencia, M., Li, Z., Mukherjee, S., Patra, D., Chen, C.-L., Klose, T., Yao, X.-Q., Kossiakoff, A. A., Chang, L., et al. (2021) · Nature · doi:10.1038/s41586-021-03721-x · Cited by 152
Bloch, J. S., Mukherjee, S., Kowal, J., Filippova, E. V., Niederer, M., Pardon, E., Steyaert, J., Kossiakoff, A. A., & Locher, K. P. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2115435118 · Cited by 114
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Hattori, T., Maso, L., Araki, K. Y., Koide, A., Hayman, J., Akkapeddi, P., Bang, I., Neel, B. G., & Koide, S. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1074 · Cited by 72
Self-citation
Metadata
- Authors
- Miller, K. R., Koide, A., Leung, B., Fitzsimmons, J., Yoder, B., Yuan, H., Jay, M., Sidhu, S. S., Koide, S., & Collins, E. J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-08-20
- Volume
- 7
- Issue
- 8
- Pages
- e43746
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1983335488
- Cited by
- 101
- References
- 2
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.